Advertisement

Aerosoltherapie

  • H. Matthys

Zusammenfassung

Die medizinische Anwendung von Aerosolen kann in schädliche (durch aerogene Umweltnoxen wie Tabakrauch, Autoabgase etc., allergogene und infektiöse Partikel, z. B. Tbc), diagnostische (Radioaerosole, vernebelte wässrige Lösungen und Suspensionen pharmakologischer und biologischer Substanzen zur bronchialen und nasalen Provokation wie Carbachol, Histamin, Metacholin, Gräserpollen etc.) und therapeutische eingeteilt werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Barnes PJ, Godfrey S (1998) Asthma therapy. Dunitz, London, pp 77–90.Google Scholar
  2. Boe J, Dennies JH, O’Driscoll BR (eds) (2000) Nebulizer guidelines: clinical aspects. Eur Resp Rev 10 (no 76).Google Scholar
  3. British Asthma Guidelines Coordination Committee (1997) British guidelines on asthma management: 1995 review and position statement. Thorax 52: S1–S24.CrossRefGoogle Scholar
  4. Köhler D (1995) Wirksamkeit und Akzeptanz von Pulverinhalatoren. Dtsch Med Wochenschr 20: 1401–1404.CrossRefGoogle Scholar
  5. Köhler D, Fleischer W (2000) Theorie und Praxis der Inhalationstherapie. Arcis, München.Google Scholar
  6. Leach CL, Davidson PJ, Boudreau RJ (1998) Improved airway targeting with CFC-free HFA-beclomethasone metered-dose inhaler compared to CFC-beclomethasone. Eur Respir J 12: 1346–1353.PubMedCrossRefGoogle Scholar
  7. Leach CL (1998) Improved delivery of inhaled steroids to large and small airways. Respir Med 92 (Suppl A): 3–8.PubMedCrossRefGoogle Scholar
  8. Matthys H (1995) Internist 36: 1005–1009.PubMedGoogle Scholar
  9. Matthys H (1998) Praxis der Aerosoltherapie. In: Scheuch G (Hrsg) Aerosole in der Inhalationstherapie II. Dustri, München, S 52–56.Google Scholar
  10. Nikander K (1994) Drug delivery systems. J Aerosol Med 7 (Suppl 1) 1–24.CrossRefGoogle Scholar
  11. Pauwels R, Newman S, Borgstrom L (1997) Airway deposition and airway effects of anti-asthmatic drugs delivered from metereddose inhalers. Eur Respir J 10: 2127–2138.PubMedCrossRefGoogle Scholar
  12. Pedersen S (1996) Inhalers and nebulizers: which to choose and why. Respir Med 90: 69–70.PubMedCrossRefGoogle Scholar
  13. The Montreal Protocol (1994) The Montreal Protocol on substances that deplete the ozone layer. Final Act. (Nairobi, UNEP 1987) Fed Reg 59: 56 276–56 298.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • H. Matthys

There are no affiliations available

Personalised recommendations